A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma

Prior treatment

• Subjects who underwent major organ surgery (excluding needle biopsy) or significant trauma within 4 weeks prior to the initial use of the investigational drug, or require elective surgery during the trial period
• Use of immunomodulatory drugs within 14 days prior to the initial use of the investigational drug, including but not limited to thymosin, interleukin, and interferon

Other illness

• Subjects with an active infection that currently requires intravenous anti-infective therapy.
• medical history of immunodeficiency including HIV antibody positive.
• The investigator believes that the subject has other conditions that may affect compliance or that are not suitable for participating in this study.

Other

• Clinically uncontrollable pleural effusion, pericardial effusion, and requiring repeated drainage or medical intervention.
• Pregnant or lactating women.

• Agree to follow the trial treatment regimen and visit schedule, voluntarily enroll, and sign the written informed consent.
• aged 18-75 years (including borderline values) at the time of signing the informed consent form
• The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) is 0\~1.
• The expected survival time is at least 12 weeks.
• According to the evaluation of RECIST 1.1 （Response Evaluation Criteria in Solid Tumours），the subjects enrolled have at least one measurable target lesion.
• Fertile men and women of childbearing age are willing to take effective contraceptive measures from the signing of the informed consent form to 6 months after the last dose of the investigational drug; women of childbearing age include premenopausal women and women who had menopause less than two years ago. Blood pregnancy test results must be negative for women of childbearing age within 7 days prior to the initial dose of the investigational drug.